Exploration of the threshold SUV for diagnosis of malignancy using 18F-FBPA PET/CT

European Journal of Hybrid Imaging

Original Article

Fumitoshi Hirokawa¹  Kentaro Fukushima²  Tsuyoshi Komori³  Teruhito Aihara³  Koji Ono³  Ryo Kakino³  Keiji Nihei³  Yasukazu Kanai⁴  Jun Hatazawa⁵  Kayako Isohashi⁵  Naonori Hu⁶  Ichiro Baba⁷ 

[1] Department of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan;Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita City,Osaka, Japan;Department of Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7, Daigaku-Machi, 569-8686, Takatsuki City, Osaka, Japan;Department of Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7, Daigaku-Machi, 569-8686, Takatsuki City, Osaka, Japan;Department of Biofunctional Analysis, Osaka Medical and Pharmaceutical University, 4-20-1, Nasahara, 569-1094, Takatsuki City, Osaka, Japan;Department of Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7, Daigaku-Machi, 569-8686, Takatsuki City, Osaka, Japan;Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, 565-0871, Suita City, Osaka, Japan;Department of Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7, Daigaku-Machi, 569-8686, Takatsuki City, Osaka, Japan;Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro Nishi, Kumatori Cho, Sennnan District, 590-0494, Osaka, Japan;Department of Orthopedic Surgery, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan;

关键词: FBPA;    FDG;    PET/CT;    SUV;    Malignancy;    Benign;   

DOI  :  10.1186/s41824-022-00156-z

 received in 2022-10-04, accepted in 2022-11-09,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundThe goal of the study was to evaluate the diagnostic ability of 18F-FBPA PET/CT for malignant tumors. Findings from 18F-FBPA and 18F-FDG PET/CT were compared with pathological diagnoses in patients with malignant tumors or benign lesions.MethodsA total of 82 patients (45 males, 37 females; median age, 63 years; age range, 20–89 years) with various types of malignant tumors or benign lesions, such as inflammation and granulomas, were examined by 18F-FDG and 18F-FBPA PET/CT. Tumor uptake of FDG or FBPA was quantified using the maximum standardized uptake value (SUVmax). The final diagnosis was confirmed by cytopathology or histopathological findings of the specimen after biopsy or surgery. A ROC curve was constructed from the SUVmax values of each PET image, and the area under the curve (AUC) and cutoff values were calculated.ResultsThe SUVmax for 18F-FDG PET/CT did not differ significantly for malignant tumors and benign lesions (10.9 ± 6.3 vs. 9.1 ± 2.7 P = 0.62), whereas SUVmax for 18F-FBPA PET/CT was significantly higher for malignant tumors (5.1 ± 3.0 vs. 2.9 ± 0.6, P < 0.001). The best SUVmax cutoffs for distinguishing malignant tumors from benign lesions were 11.16 for 18F-FDG PET/CT (sensitivity 0.909, specificity 0.390) and 3.24 for 18F-FBPA PET/CT (sensitivity 0.818, specificity 0.753). ROC analysis showed significantly different AUC values for 18F-FDG and 18F-FBPA PET/CT (0.547 vs. 0.834, p < 0.001).Conclusion18F-FBPA PET/CT showed superior diagnostic ability over 18F-FDG PET/CT in differential diagnosis of malignant tumors and benign lesions. The results of this study suggest that 18F-FBPA PET/CT diagnosis may reduce false-positive 18F-FDG PET/CT diagnoses.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

12982_2022_119_Article_IEq195.gif

12888_2022_4392_Article_IEq2.gif

12888_2022_4392_Article_IEq1.gif

12982_2022_119_Article_IEq50.gif

12982_2022_119_Article_IEq186.gif

12982_2022_119_Article_IEq184.gif